Comprehensive Physiology Wiley Online Library

Endocrine Hypertension

Full Article on Wiley Online Library


The sections in this article are:

1 Corticosteroids
1.1 Mineralocorticoid Hypertension
1.2 Glucocorticoid Hypertension
2 Renin–Angiotensin System
3 Catecholamines
3.1 Pheochromocytoma
4 Insulin and Growth Hormone
5 Vascular Hormones: Endothelin and Nitric Oxide
6 Sodium‐Losing Hormones
7 Summary
 1. Agarwal, A. K., C., Monder, B. Eckstein, and P. C. White. Cloning and expression of rat cDNA encoding corticosteroid 11 β‐dehydrogenase. J. Biol Chem. 264: 18939–18943, 1989.
 2. Alioa, J. F., M. S. Roginsky, J. Jowsey, C. S. Dombrowski, K. K. Shunkla, and S. H. Cohn. Skeletal metabolism and body composition in acromegaly. J. Clin. Endocrinol. Metab. 35: 543–551, 1972.
 3. Allerman, Y., and P. Weidmann. Cardiovascular, metabolic and hormonal dysregulations in normotensive offspring of essential hypertensive patients. J. Hypertens. 13: 163–173, 1995.
 4. Alquist, R. P.. A study of the adrenotropic receptors. Am. J. Physiol. 153: 586–600, 1948.
 5. Arai, K., and G. P. Chrousos. Glucocorticoid resistance. Bailleres Clin. Endocrinol. Metab. 8: 317–331, 1994.
 6. Atlas, S. A.. Atrial natriuretic factor: a new hormone of cardiac origin. Recent Prog. Horm. Res. 42: 207–241, 1986.
 7. Axelrod L.. Inhibition of prostacyclin production mediates permissive effect of glucocorticoids on vascular tone. Lancet 1: 904–906, 1983.
 8. Baer L., S. C. Sommers, L. R. Krakoff, M. A. Newton, and J. H. Laragh. Pseudo‐primary aldosteronism. An entity distinct from true primary aldosteronism. Circ. Res. 27 (Suppl. I): I205–I220, 1970.
 9. Bakris G. L.. Hypertension in diabetic patients. An overview of interventional studies to preserve renal function. Am. J. Hypertens. 6: 1405–1475, 1993.
 10. Ballerman B. J., and B. M. Brenner. Role of atrial peptides in body fluid homeostasis. Circ. Res. 58: 619–630, 1986.
 11. Banskota N. K., R. Taub, K. Zellner, and G. L. King. Insulinlike growth factor and PDGF interact additively in the induction of the proto‐oncogene c‐myc in cellular proliferation in cultured bovine aortic smooth muscle cells. Mol. Endocrinol. 3: 1183–1190, 1989.
 12. Bean B. L., J. J. Brown, and J. Casals‐Stenzel. The relation of arterial pressure and plasma angiotensin II in the conscious dog: a change produced by prolonged infusion. Circ. Res. 44: 452–458, 1979.
 13. Beretta‐Piccoli, C., Diabetes mellitus and hypertension. In: Handbook of Hypertension. Clinical Hypertension, edited by J. I. S. Robertson. Amsterdam: Elsevier, 1992, vol. 15, p. 141–176.
 14. Beretta‐Piccoli, C., D. L. Davies, K. Boddy, J. J. Brown, A. M. M. Cumming, B. W. East, R. Fraser, A. F. Lever, P. L. Padfield, P. F. Semple, J. I. S. Robertson, P. Weidmann, and E. D. Williams. Relation of arterial pressure with body sodium, body potassium and plasma potassium in essential hypertension. Clin. Sci. (Colch.) 63: 257–270, 1982.
 15. Beretta‐Piccola, C., D. L., Davies, J. J. Brown, J. B. Ferris, R. Fraser, A. F. Lever, J. J. Morton, and J. I. S. Robertson. The relation of arterial pressure with plasma and body electrolyte is similiar in Conn's syndrome and essential hypertension. Clin. Sci. (Colch.) 63: 89s–92s, 1982.
 16. Beretta‐Piccoli, C., and P. Weidmann. Body sodium‐blood volume state in nonazotaemic diabetes mellitus. Miner. Electrolyte Metab. 7: 36–47, 1982.
 17. Biglieri, E. G., M. A., Herron, and N. Brust. 17–Hydroxylation deficiency in man. J. Clin. Invest. 45: 1946–1954, 1966.
 18. Biglieri, E. G., C. O., Watlington, and P. H. Forsham. Sodium retention with human growth hormone and its subfractions. J. Clin. Endocrinol. Metab. 21: 361–370, 1961.
 19. Bing, R. J., A., Termin, A. Conforto, R. Dudek, and M. J. Hoffman. Membrane function and vascular reactivity. Biosci. Rep. 13: 61–67, 1993.
 20. Bobik, A., and J. H. Campbell. Vascular‐derived growth factors: cell biology, pathophysiology and pharmacology. Pharmacol. Rev. 45: 1–42, 1993.
 21. Bogardus, C., S., Lillioja, K. Stone, and D. Mott. Correlation between muscle glycogen synthase activity and in vitro insulin action in man. J. Clin. Invest. 80: 415–425, 1987.
 22. Bolli, P., W., Kiowski, and F. R. Buhler, The pathophysiology of the sympathetic nervous system in human hypertension: studies using specific pharmacological probes. In: Hypertension. Pathophysiology, Diagnosis and Management, edited by J. H. Laragh and B. M. Brenner. New York: Raven, 1995, p. 923–940.
 23. Boulanger, C. M., and T. F. Luscher. Release of endothelin from the porcine aorta: inhibition by endothelium‐derived nitric oxide. J. Clin. Invest. 85: 587–590, 1992.
 24. Bronnegard, M., S., Werner, and J.‐A. Gustafsson. Primary Cortisol resistance associated with a thermolabile glucocorticoid receptor in a patient with fatigue as the only symptom. J. Clin. Invest. 78: 1270–1278, 1986.
 25. Brown, A. J., J., Casals‐Stenzel, and S. Goffard. Comparison of fast and slow pressor effects of angiotension II in the conscious rat. Am. J. Physiol. 241 (Heart Circ. Physiol. 12): H381–H388, 1981.
 26. Brown, J. J., J., Casals‐Stenzel, A. M. M. Cumming, D. L. Davies, R. Fraser, and A. F. Lever. Angiotensin II, aldosterone and arterial pressure: a quantitative approach. Hypertension 1: 159–179, 1979.
 27. Brown, M. J., Is epinephrine the cause of essential hypertension? In: Essential hypertension as an Endocrine Disease, London: Butterworth, 1985, p. 40–61.
 28. Brown, R. W., K. E., Chapman, C. R. W. Edwards, and J. R. Seckl. Human placental 11β‐hydroxysteroid dehydrogenase. Evidence for and partial purification of distinct NAD‐dependent isoform. Endocrinology 132: 2614–2621, 1993.
 29. Buchannan, T. A. G. F. Sipos, S. Gadalam, K. P. Yip, D. J. March, and W. Hsueh. Glucose tolerance and insulin action in rats with renovascular hypertension. Hypertension 18: 341–347, 1991.
 30. Buchanan, T. A., H., Thawani, W. Kades, J. G. Modrall, F. A. Weaver, and C. Laurel. Angiotensin II increases glucose utilisation during acute hyperinsulinaemia via a dynamic mechanism. J. Clin. Invest. 92: 720–726, 1993.
 31. Buckley, M. G., N. D., Markandu, G. A. Sagnella, and G. A. MacGregor. Brain and atrial natriuretic peptides: a dual peptide system of potential importance in sodium balance and blood pressure regulation in patients with essential hypetension. J. Hypertens. 12: 809–813, 1994.
 32. Bursztyn, M., D. Ben‐Ishay, A. Gutman. Insulin resistance in spontaneously hypertensive rats but not in DOCA‐salt or renal vascular hypertension. J. Hypertens. 10: 137–140, 1992.
 33. Campbell, D. J.. Circulating and tissue angiotensin systems. J. Clin. Invest. 79: 1–6, 1987.
 34. Campbell, W. B., M. G., Curri, and P. Needleman. Inhibition of aldosterone biosynthesis by atrial peptides in rat adrenal cells. Circ. Res. 57: 113–118, 1985.
 35. Chalmers, J., L., Arnolda, I. Llewellyn‐Smith, J. Minson, P. Pilowsky, Central nervous control of blood pressure. In: Textbook of Hypertension, edited by J. D. Swales. Oxford: Blackwell, 1994, p. 409–427.
 36. Chalmers, J., and P. Pilowsky. Brainstem and bulbospinal neurotransmitter systems in the control of blood pressure. J. Hypertens. 9: 675–694, 1991.
 37. Chartier, L., E., Schiffrin, and G. Thibault. Effect of atrial natriuretic factor (ANF)–related peptides on aldosterone production in adrenal zona glomerulosa cells. Biochem. Biophys. Res. Commun. 122: 171–174, 1984.
 38. Chen, P. Y., and P. W. Sander. L‐Arginine abrogates salt‐sensitive hypertension in Dahl/Rapp rats. J. Clin. Invest. 88: 1559–1567, 1991.
 39. Christiansen, J. S., J., Gammelgaar, J. Orsko, A. R. Anderso, S. Telm, and H. H. Parvin. Kidney function and size in normal subjects before and during growth hormone administration for one week. Eur. J. Clin. Invest. 11: 487–490, 1981.
 40. Chrousos, G. P., and M. Karl, The molecular mechanisms of glucocorticoid resistance. In: Cellular and Molecular Biology of the Adrenal Cortex, edited by J. M. Saez, A. C. Brownie, A. Capponi, E. M. Chambaz, and F. Mantero. Paris: Colloque IN‐SERM, 1992, p. 227–232.
 41. Chu, M., and S. Ulick. Isolation and identification of 18‐hydroxycortisol from the urine of patients with primary aldosteronism. J. Biol. Chem. 258: 2218–2224, 1982.
 42. Clauser, E., K. M., Curnow, E. Davies, S. Concho, B. Teutsch, B. Vianell, C. Monnot, and P. Corvol. Angiotensin II receptors: protein and gene structure, expression and potential pathological involvements. Eur. J. Endocrinol. 134: 403–411, 1996.
 43. Cockroft, J. R., P. J., Chowienczyck, and J. M. Ritter. Preserved endothelium‐dependent vasodilatation in patients with essential hypertension. N. Engl. J. Med. 330: 1036–1040, 1994.
 44. Cohen, R. A.. The role of nitric oxide and other endothelium‐derived vasoactive substances in vascular disease. Prog. Cardiovasc. Dis. 38: 105–128, 1995.
 45. Conn, J. W.. Primary aldosteronism: a new clinical syndrome. J. Lab. Clin. Med. 45: 6–17, 1955.
 46. Conn, J. W., E. L., Cohen, C. L. Lucas, W. McDonald, G. H. Mayor, and W. M. Blough. Primary reninism: hypertension, hyperreninaemia and secondary aldosteronism due to renin‐producing juxtaglomerular cell tumours. Arch. Intern. Med. 30: 682–696, 1972.
 47. Connell, J. M. C., B. M., Fisher, G. Davidson, R. Fraser, and J. A. Whitworth. Effects of sodium depletion on pressor responsiveness in ACTH‐induced hypertension in man. Clin. Exp. Pharmacol. Physiol. 14: 237–242, 1987.
 48. Connell, J. M. C., G. C., Inglis, R. Fraser, and A. Jamieson. Dexamethasone‐suppressible hyperaldosteronism: clinical, biochemical and genetic relations. J. Hum. Hypertens. 9: 505–509, 1995.
 49. Connell, J. M. C., C. J., Kenyon, J. E. T. Corrie, R. Fraser, R. Watt, and A. F. Lever. Dexamethasone‐suppressible hyperaldosteronism. Adrenal transition cell hyperplasia? Hypertension 8: 669–676, 1986.
 50. Connell, J. M. C., J. A., Whitworth, D. L. Davies, A. F. Lever, A. M. Richards, and R. Fraser. Effects of ACTH and Cortisol administration on blood pressure, electrolyte metabolism, atrial natriuretic peptide and renal function in normal man. J. Hypertens. 5: 425–433, 1987.
 51. Connell, J. M. C., J. A., Whitworth, D. L. Davies, A. M. Richards, and R. Fraser. Haemodynamic hormonal and renal effects of adrenocorticotrophic hormone in sodium‐restricted man. J. Hypertens. 6: 17–23, 1988.
 52. Corvilain, J., M., Abramow, and A. Bergans. Some effects of human growth hormone on renal haemodynamics and on tubular phosphate transport in man. J. Clin. Invest. 41: 1230–1235, 1962.
 53. Creager, M. A., C.‐S., Liang, and J. D. Coffman. Beta adrenergic‐mediated vasodilator response to insulin in the human forearm. J. Pharmacol. Exp. Ther. 235: 709–714, 1985.
 54. Cruikshank, J. M., and B. N. C. Pritchard, Beta‐blockers. In: Textbook of Hypertension, edited by J. D. Swales. Oxford: Blackwell, 1994, p. 1059–1088.
 55. Cuneo, R. C., E. A., Espiner, M. G. Nicholls, T. G. Yandle, and J. H. Livesey. Effect of physiological levels of atrial natriuretic peptide on hormone secretion; inhibition of angiotensin‐induced aldosterone secretion and renin release in normal man. J. Clin. Endocrinol. Metab. 65: 765–772, 1987.
 56. Davenport, A. B., M. J., Ashby, P. Easton, S. Ella, J. Bedford, C. Dickerson, D. J. Nunez, S. J. Capper, and M. J. Brown. A sensitive radioimmunoassay measuring endothelin‐like activity in human plasma; comparison of patients with essential hypertension and normotensive control subjects. Clin. Sci. (Colch.) 78: 261–264, 1990.
 57. Davidson, N. C., and A. D. Struthers. Brain natriuretic peptide. J. Hypertens. 12: 329–336, 1994.
 58. Davies, D. L., G. H., Beastall, J. M. C. Connell, R. Fraser, D. McCruden, and G. M. Teasdale. Body composition, blood pressure and the renin–angiotensin system in acromegaly before and after treatment. J. Hypertens. 3 (Suppl. 3): S413–S415, 1985.
 59. Davies, D. L., D. G., Beevers, J. J. Brown, A. M. M. Cumming, R. Fraser, A. F. Lever, P. A. Mason, J. J. Morton, J. I. S. Robertson, M. Titterington, and M. Tree. Aldosterone and its stimuli in normal and hypertensive man: are essential hypertension and primary hyperaldosteronism without tumour the same condition? J. Endocrinol. 81: 79P–91P, 1979.
 60. Davies, D. L., J. M. C., Connell, R. Reid, and R. Fraser, Acromegaly: the effects of growth hormone on blood vessels, sodium homeostasis and blood pressure. In: Handbook of Hypertension. Clinical Hypertension, edited by J. I. S. Robertson. Amsterdam: Elsevier, 1992, vol. 15, p. 545–593.
 61. de Macedo, M. G., D. Trigueiros, and A. F. Freitas. Aggregation of blood pressure in families: genetic and environmental influences. J. Hum. Hypertens. 4: 303–306, 1990.
 62. Deray, G., M., Rieu, M. A. Devynck, M. G. Pernollet, P. Chanson, J. P. Luton, and P. Meyer. Evidence of an endogenous digitalis‐like factor in the plasma of patients with acromegaly. N. Engl. J. Med. 316: 575–580, 1987.
 63. Dessi‐Fulgheri, P., R. Palermo, G. Di Noto, V. Conti, L. Rinaldi, G. Tesei, P. Russo, and A. Rappelli. Plasma levels of atrial natriuretic factor in mild to moderate hypertensives without signs of left ventricular hypertrophy: correlation with the known duration of hypertension. J. Hum. Hypertens. 2: 177–182, 1988.
 64. Diederich, D., Z., Yang, and F. R. Buhler. Impaired endothelium‐dependent relaxations in hypertensive resistance arteries involve cyclooxygenase pathway. Am. J. Physiol. 258 (Heart Circ. Physiol. 29): H445–H451, 1990.
 65. De Fronzo, R. A.. The effects of insulin on renal sodium. Diabetologia 21: 165–171, 1981.
 66. De Kloet, R. E.. Brain corticosteroid receptor balance and homeostatic control. Front. Neuroendocrinal. 12: 95–164, 1991.
 67. Derkx, F. H. M., and M. A. D. H. Schalekamp. Human prorenin: pathophysiology and clinical implications. Clin. Exp. Hyper. Theor. Pract. A10: 1213–1225, 1988.
 68. de Simone, G., A. Tomaselli, R. Rossi, R. Valentino, R. Lauria, F. Scopocasa and G. Lombardi. Partial deficiency of adrenal 11β‐hydroxylase—a possible cause of primary hypertension. Hypertension 7: 204–210, 1985.
 69. Devlin, A. M., A. O., Davidson, J. F. Gordon, A. M. Campbell, J. J. Morton, J. L. Reid, and A. F. Dominiczak. Vascular smooth muscle polyploidy in genetic hypertension: the role of angiotensin II. J. Hum. Hypertens. 9: 497–500, 1995.
 70. DiBona, G. F.. Neural regulation of renal tubular sodium reabsorption and renin secretion: integrative aspects. Clin. Exp. Hypertens. A9 (Suppl. 1): 151–163, 1987.
 71. Dominiczak, A. F., and D. F. Bohr. Nitric oxide and its putative role in hypertension. Hypertension 25: 1202–1211, 1995.
 72. Douglas, S. A., M., Gellai, M. Ezekiel, and E. H. Ohlstein. BQ‐123, a selective endothelin subtype A receptor antagonist, lowers blood pressure in different rat models of hypertension. J. Hypertens. 12: 561–567, 1994.
 73. Dubin, D., R. E., Pratt, J. P. Cooke, and V. J. Dzau. Endothelin, a potent vasoconstrictor is a vascular smooth muscle mitogen. J. Vasc. Med. Biol. 1: 150–154, 1989.
 74. Dzau, V. J., A., Brenner, N. Emmett, and E. Haber. Identification of renin and renin‐like enzymes in rat brain by renin specific antibody. Clin. Sci. (Colch.) 59: 45s–47s, 1980.
 75. Dzau, V. J., D. W., Burt, and R. E. Pratt. Molecular biology of the renin–angiotensin system. Am. J. Physiol. 255 (Renal Fluid Electrolyte Physiol. 26): F563–F573, 1988.
 76. Dzau, V. J., and R. E Pratt, Renin–angiotensin system: biology, physiology and pharmacology. In: Handbook of Experimental Cardiology, edited by E. Haber, H. Morgan, Z. Katz, and H. Fozzard. New York: Raven, 1986, p. 1631–1661.
 77. Eade, I, E., Layning, and F. Kiil. Evidence for haemodynamic autoregulation of renin release. Circ. Res. 32: 237–245, 1973.
 78. Eberhardt, R. T., R. M., Kevak, P. M. Kan, and W. H. Frishman. Angiotensin II receptor blockade: an innovative approach to cardiovascular pharmacotherapy. J. Clin. Pharmacol. 33: 1023–1038, 1993.
 79. Eberlein, W. R., and A. M. Bongiovanni. Congenital adrenal hyperplasia with hypertension: unusual steroid pattern in blood and urine. J. Clin. Endocrinol. Metab. 15: 1531–1534, 1955.
 80. Emori, T., Y., Hirata, Y. Ohta, K. Kanno, S. Eguchi, T. T. Imai, M. Schichiri, and F. Marumo. Cellular mechanism of endothelin I release by angiotensin and vasopressin. Hypertension 18: 165–170, 1991.
 81. Encio, I. J., and S. D. Detera‐Wadleigh. The genomic structure of the human glucocorticoid receptor. J. Biol. Chem. 266: 7128–7188, 1991.
 82. Esler, M., G., Jennings, P. Korner, I. Willett, F. Dudley, G. Hasking, W. Anderson, and G. Lambert. Assessment of human sympathetic nervous system activity from measurements of noradrenaline turnover. Hypertension 11: 3–20, 1988.
 83. Feldt‐Rasmussen, B., E. R., Mathiesen, T. Deckert, J. Giese, N. J. Christensen, L. Bent‐Hansen, and M. D. Nielsen. Central role for sodium in the pathogenesis of blood pressure changes independent of angiotensin, aldosterone and catecholamines in type I (insulin‐dependent) diabetes mellitus. Diabetologia 30: 610–617, 1987.
 84. J. B. Ferriso, Primary hyperaldosteronism: Conn's syndrome and similar disorders. In: Handbook of Hypertension. Clinical Hypertension, edited by J. I. S. Robertson. Amsterdam: Elsevier, 1992, vol. 15, p. 357–389.
 85. Floras, J. S.. Epinephrine and the genesis of hypertension. Hypertension 19: 1–18, 1992.
 86. Forstermann, U., J. S., Pollock and M. Nakane. Nitric oxide synthases and the cardiovascular system. Trends Cardiovasc Med. 3: 104–110, 1993.
 87. Fraser, R., Biosynthesis of adrenocortical steroids. In: The Adrenal Gland, edited by V. H. T. James. New York: Raven, 1992, p. 117–130.
 88. Fraser, R., Inborn errors of corticosteroid biosynthesis and metabolism: their effects on electrolyte metabolism. In: Handbook of Hypertension. Clinical Hypertension, edited by J. I. S. Roberson. Amsterdam: Elsevier, 1992, vol. 15, p. 420–460.
 89. Fraser, R., C., Beretta‐Piccoli, J. J. Brown, A. M. M. Cumming, A. F. Lever, P. A. Mason, J. J. Morton and J. I. S. Robertson. Response of aldosterone and 18‐hydroxycorticosterone to angiotensin II in normal subjects and patients with essential hypertension, Conn's syndrome and non‐tumorous hyperaldosteronism. Hypertension 3 (Suppl. I): I‐87–I‐92, 1981.
 90. Fraser, R., D. L., Davies, and J. M. C. Connell. Hormones and hypertension. Clin. Endocrinol. (Oxf.) 31: 701–746, 1989.
 91. Fraser, R., and P. L. Padfield, Role of mineralocorticoids in essential hypertension. In: Essential Hypertension as an Endocrine Disease, edited by C. R. W. Edwards, and R. M. Carey. London: Butterworth, 1985, p. 158–183.
 92. Fray, J. C. S.. Stretch receptor model for renin release with evidence from perfused rat kidney. Am. J. Physiol. 231: 936–944, 1976.
 93. Freeman, R. H., J. O., Davis, and D. Villareal. Role of renal prostaglandins in the control of renin release. Circ. Res. 54: 1–9, 1984.
 94. Fujita, N., T., Baba, T. Tomiyami, T. Kodama and N. Kako. Hyperinsulinaemia and blood pressure in patients with insulinoma. BMJ 304: 1157, 1992.
 95. Funder, J. W., P. T., Pearce, R. Smith, and A. J. Smith. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 242: 583–585, 1988.
 96. Gaillard, I., E. Clauser, and P. Corvol. Structure of human angiotensinogen gene. DNA 8: 87–99, 1989.
 97. Gaillard, R. C., D., Poffet, A. M. Riandel, and J. Saurat. RU486 inhibits peripheral effects of glucocorticoids in humans. J. Clin. Endocrinol. Metab. 61: 1009–1011, 1985.
 98. Gaillard‐Sanchez, I., M. G., Mattei, E. Clauser, and P. Corvol. Assignment by in situ hybridisation of the angiotensinogen gene to chromosome band Iq4. Hum. Genet. 84: 341–343, 1990.
 99. Ganguly, A.. Cellular origin of aldosteromas. Clin. Invest. 70: 392–395, 1992.
 100. Ganten, D., U., Ganten, S. Kubo, P. Granger, W. Nowaczynski, and R. Boucher. Influence of sodium, potassium and pituitary hormones on iso‐renin in rat adrenal glands. Am. J. Physiol. 227: 224–229, 1974.
 101. Garg, V. C., and A. Hassid. Nitric oxide–generating vasodilators and 8‐bromo‐cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J. Clin. Invest. 83: 1774–1777, 1989.
 102. Gavras, H., D., Handy, and I. Gavras, Alpha‐adrenergic receptors in hypertension. In: Hypertension. Pathophysiology, Diagnosis and Management, edited by J. H. Laragh, B. M. Brenner. New York: Raven, 1995, p. 853–861.
 103. Geisterfer, A., M. J, Peach, and G. K. Owens. Angiotensin II induces hypertrophy, not hyperplasia in cultured rat aortic smooth muscle cells. Circ. Res. 62: 749–756, 1988.
 104. Gicquel, C., X. Bertagna, and Y. Le Bouc. Recent advances in the pathogenesis of adrenocortical tumours. Eur. J. Endocrinol. 133: 133–144, 1995.
 105. Glorioso, N., S. A., Atalas, J. H. Laragh, R. Jewelewicz and J. E. Sealey. Prorenin in high concentrations in human ovarian follicular fluid. Science 233: 1422–1424, 1986.
 106. Gomez Sanchez, E. P.. Mineralocorticoid modulation of central control of blood pressure. Steroids 60: 69–72, 1995.
 107. Gordon, R. D., M., Stowasser, S. A. Klemm, and T. J. Tunny. Primary aldosteronism—some genetic, morphological and biochemical aspects of subtypes. Steroids 60: 35–41, 1995.
 108. Gordon, R. D., M., Stowasser, T. J. Tunny, S. A. Klemm, and J. C. Rutherford. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin. Exp. Pharmacol. Physiol. 21: 315–318, 1994.
 109. Gordon, R. D., M. D., Ziesak, T. J. Tunny, M. Stowasser, and S. A. Klemm. Evidence that primary aldosteronism may not be uncommon—12% incidence among antihypertensive drug trial volunteers. Clin. Exp. Pharmacol. Physiol. 20: 296–298, 1993.
 110. Goto, A., K., Yamada, N. Yagi, N. Yoshioka and T. Sugimoto. Physiology and pharmacology of endogenous digitalis‐like factors. Pharmacol. Rev. 44: 377–399, 1992.
 111. Grassi, G.. Evaluating sympathetic and haemodynamic responses to mental stressors: hankering or achievement. J. Hypertens. 14: 1155–1157, 1996.
 112. Greminger, P., W., Tenschert, and W. Vetter, Hypertension in Cushing's syndrome. In: Endocrinology of Hypertension, edited by F. Mantero and E. G. Biglieri. London: Academic, 1982, p. 103–110.
 113. Griendling, K. K., and R. W. Alexander, Cellular mechanisms of angiotensin II action. In: Textbook of Hypertension, edited by J. D. Swales. London: Blackwell, 1994 , p. 244–252.
 114. Grunfeld, J. P., L., Eldy, A. M. Movra, D. Ganeval, B. Ramos‐Frendo, and M. Worcel. Effects of antiglucocorticoids in glucorticoid hypertension in the rat. Hypertension 7: 292–299, 1985.
 115. Hackenthal, E., M., Paul, D. Ganten, and R. Taugner. Morphology, physiology and molecular biology of renin secretion. Physiol. Rev. 70: 1067–1116, 1990.
 116. Haigh, R. M., and C. T. Jones. The effect of glucocorticoids on α1‐adrenergic receptor binding in rat vascular smooth muscle. J. Mol. Endocrinol. 5: 41–48, 1990.
 117. Halimi, J., F. Gahnam D. Marion, and J. E. Sealey. Protein feeding increases plasma prorenin in dogs. J. Hypertens. 10 (Suppl.): S124, 1992.
 118. Hall, A. S. and S. G., Ball, Pheochromocytoma. In: Handbook of Hypertension. Clinical Hypertension, edited by J. I. S. Robertson. Amsterdam: Elsevier, 1992, vol. 15, p. 494–544.
 119. Hamlyn, J. M., and P. Manunta. Ouabain, digitalis‐like factors and hypertension. J. Hypertens. 10 (Suppl. 7): S99–S111, 1992.
 120. Hardmann, J. A., Y. J., Hart, D. F. Cantanzaro, J. T. Telman, J. D. Baxter and B. Morris. Primary structure of the human renin gene. DNA 3: 457–467, 1984.
 121. Harrap, S. B., F., MacPherson, V. G. Wilson, D. L. Davies, O. P. G. Isaksson, B. Folkow, and A. F. Lever. Failure of chronic administration of growth hormone to affect blood pressure, vascular reactivity and sodium metabolism in normal rats. J. Hypertens. 6 (Suppl. 14): S170–S172, 1988.
 122. Haynes, W. G.. Endothelins as regulators of vascular tone on man. Clin. Sci.(Colch.) 88: 509–517, 1995.
 123. Haynes, W. G., and D. J. Webb. The endothelin family of peptides: local hormones with diverse roles in health and disease? Clin. Sci., Colch.) 84: 485–500, 1993.
 124. Herrera, V. L. M., and N. Ruiz‐Opazo. Beyond genetic markers: hypertension genes. J. Hypertens. 12: 847–856, 1994.
 125. Hobart, P. M., M., Fogliano, B. A. O'Connor, I. M. Schaefer, and J. M. Chirgwin. Human renin gene: structure and sequence analysis. Proc. Natl. Acad. Sci. U.S.A. 81: 5026–5030, 1984.
 126. Honeyman, T. W., H. M., Goodman, and J. C. S. Fray. The effects of growth hormone on blood pressure and renin secretion in hypophysized rats. Endocrinology 112: 1613–1617, 1983.
 127. Horio, T., M., Kohno and T. Takeda. Effects of vasopressin, angiotensin II and endothelin‐1 on the release of brain natriuretic peptide in vivo and in vitro. Clin. Exp. Pharmacol. Physiol. 19: 575–582, 1992.
 128. Howlett, T. A., P. L., Drury, L. Perry, I. Doniach, L. H. Rees, and G. M. Besser. Diagnosis and management of ACTH‐dependent Cushing's syndrome: comparison of the features in ectopic and pituitary ACTH production. Clin. Endocrinol. Oxf. 24: 699–713, 1986.
 129. Hubert, C., A. M., Honor, P. Corvol and F. Soubrier. Structure of the angiotensin I converting enzyme gene. J. Biol. Chem. 264: 11945–11951, 1991.
 130. Hypertension and Diabetes Study Group. Hypertension in diabetes study 1. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J. Hypertens. 11: 309–317, 1993.
 131. Imai, T., T., Yanase, M. Waterman, E. Simpson, and J. Pratt. Canadian Mennonites and individuals residing in the Friesl region of the Netherlands share the same molecular basis of 17α‐hydroxylase deficiency. Hum. Genet. 89: 95–96, 1992.
 132. Imura, O., K., Shimamoto, D. Hotta, T. Nakata, T. Mito, Y. Kumamoto. A case of adrenal tumour producing renin, aldosterone and sex steroid hormones. Hypertension 8: 951–956, 1986.
 133. Inagami, T., Intracellular renin: validation and functions. In: The Renin‐Angiotensin System, edited by J. I. S. Robertson and M. G. Nicholls. London: Gower, 1993, vol. 1, 30.1–30.8.
 134. Inoue, A., M., Yanigisawa, S. Kimura, Y. Kasuya, T. Miyauchi and K. Goto. The human endothelin family; three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc. Natl. Acad. Sci. U.S.A. 86: 2863–2867, 1989.
 135. Isles, C. G., I. C., MacDougall, A. F. Lever, and R. Fraser. Hypermineralocorticoidism due to adrenal carcinoma: plasma corticosteroids and their response to ACTH and angiotensin II. Clin. Endocrinol. (Oxf.) 26: 239–251, 1987.
 136. Itskovitz, J., S., Rabattu, J. Kevron, and J. E. Sealey. Highest concentrations of prorenin and human chorionic gonadotrophin in gestational sacs during early human pregnancy. J. Clin. Endocrinol. Metab. 75: 906–910, 1992.
 137. Jamieson A., and R. Fraser. Developments in the molecular biology of corticosteroid synthesis and action: implications for an understanding of essential hypertension. J. Hypertens. 12: 503–509, 1994.
 138. Jamieson, A., G. C., Inglis, M. Campbell, R. Fraser, and J. M. C. Connell. Rapid diagnosis of glucocorticoid‐suppressible hyperaldosteronism in infants and adolescents. Arch. Dis. Child. 71: 40–43, 1994.
 139. Jamieson, A., M. C., Ingram, G. C. Inglis, E. Davies, R. Fraser, and J. M. C. Connell. Altered 11β‐hydroxylase activity in glucocorticoid‐suppressible hyperaldosteronism. J. Clin. Endocrinol. Metab. (in press), 1996.
 140. Jamieson, A., L., Slutsker, G. C. Inglis, R. Fraser, P. C. White, and J. M. C. Connell. Glucocorticoid‐suppressible hyperaldosteronism: effects of crossover site and parental origin of chimaeric gene on phenotype expression. Clin. Sci. (Colch.) 88: 563–570, 1995.
 141. Jazayer, A., and W. Meyer. Glucocorticoid modulation of β‐adrenergic receptors in cultured rat arterial smooth muscle cells. Hypertension 12: 393–398, 1988.
 142. Johnson, R. A., and R. H. Freeman. Sustained hypertension in the rat induced by chronic blockade by nitric oxide production. Am. J. Hypertens. 5: 919–922, 1992.
 143. Kalsner, S.. Mechanisms of hydrocortisone potentiation of responses to epinephrine and norepinephrine in rabbit aorta. Circ. Res. 24: 383–395, 1969.
 144. Kaplan, N. M., Clinical Hypertension. Baltimore: Williams and Wilkins, 1994.
 145. Kato, I., Y., Iwana, and K. Okamura. Prostaglandin H2 may be the endothelium‐derived contracting factor released by acetylcholine in the aorta of the rat. Hypertension 15: 475–481, 1990.
 146. Kenyon, C. J., W. B., Brown, R. Fraser, G. Tonolo, F. McPherson, and D. L. Davies. Effects of dexamethasone on body fluid and electrolyte composition of rats. Acta Endocrinol. (Copenh.) 122: 599–604, 1990.
 147. Kimura, G., F., Saito, S. Kojima, H. Yoshimi, H. Abe, Y. Kawano, K. Yoshida, T. Ashida, M. Kawamura, M. Kwamochi, Ito, K. T. Omae. Renal function curve in patients with secondary forms of hypertension. Hypertension 10: 11–15, 1987.
 148. Kirschner, K. A., P. H., Scanlon, and D. J. Dzielak. Endothelium‐derived relaxing factor responses in DOCA‐salt hypertensive rats. Am. J. Physiol. 265 (Regulatory Integrative Comp. Physiol. 36): R568–R572, 1993.
 149. Kobilka, B., and B. B. Hoffman, Molecular characteristics and regulation of adrenergic receptors. In: Hypertension. Pathophysiology, Diagnosis and Management, edited by J. H. Laragh and B. M. Brenner. New York: Raven, 1995, p. 841–851.
 150. Kohno, M., K. Yasunari, K. I. Murakawa. Plasma immunoreactive endothelin in essential hypertension. Am. J. Med. 88: 614–618, 1990.
 151. Kohno, M., K., Yasunari, K. Murakawa, Y. Kanayama, T. Matsuura, and T. Takeda. Effects of high sodium and low sodium intake on circulating atrial natriuretic peptides in salt sensitive patients with systemic hypertension. Am. J. Cardiol. 59: 1212–1213, 1987.
 152. Kohno, M., K., Yasunari, K. Yokokawak, K. Murakawa, T. Horio, and T. Takeda. Inhibition by atrial and brain natriuretic peptides of endothelin‐1 secretory response to angiotensin II in porcine aorta. Circ. Res. 70: 241–247, 1992.
 153. Kornel, L., W. R., Starnes, S. R. Hill, and A. Hill. Studies on steroid conjugates, vi. Quantitative paper chromatography of urinary corticosteroids in essential hypertension. J. Clin. Endocrinol. Metab. 29: 1608–1617, 1969.
 154. Korner, P. I.. Circulatory control and the supercontrollers. J. Hypertens. 13: 1508–1521, 1995.
 155. Kotanke, P., A., Binder, J. Tasker, P. DeFreitas, S. Kamdar, A. J. L. Clark, F. Skrabal, and M. Caulfield. Essential hypertension in Afro‐Caribbeans associates with a variant of the β2‐adrenoreceptor. Hypertension 30: 773–776, 1997.
 156. Kowski, W., T. F., Luscher, L. Linder, and F. L. Buhler. Endothelin 1‐induced vasoconstriction in humans. Reversal by calcium channel blockade but not by nitrovasodilators or endothelium‐derived relaxing factor. Circulation 83: 469–475, 1991.
 157. Kurihora, Y., H., Kurihara, H. Susuki, et al, Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin 1. Nature 368: 703–710, 1994.
 158. Kurtz, A., B., Kaissling, R. Busse, and W. Baier. Endothelial cells modulate renin secretion from isolated mouse juxtaglomerular cells. J. Clin. Invest. 88: 1147–1154, 1991.
 159. Lamberts, S. W., J. W., Koper, P. Bernod, F. H. den Holder, and F. H. de Jong. Cortisol receptor resistance: the variability of its clinical presentation and response to treatment. J. Clin. Endocrinol. Metab. 74: 313–321, 1992.
 160. Lan, N. C., B., Graham, F. C. Bartter, and J. D. Baxter. Binding of steroids to mineralocorticoid receptors: implications for in vivo occupancy by glucocorticoids. J. Clin. Endocrinol. Metab. 54: 332–342, 1982.
 161. Lands, W. E. M.. The biosynthesis and metabolism of prostaglandins. Annu. Rev. Physiol. 41: 633–642, 1979.
 162. Landsberg, L., and J. B. Young, Catecholamines and the adrenal medulla. In: Metabolic Control and Disease, edited by P. K. Bondy, and L. E. Rosenburg. Philadelphia: Saunders, 1980, p. 1621–1693.
 163. Langer, S. Z., and P. E. Hicks. Physiology of the sympathetic nerve ending. Br. J. Anaesth. 56: 689–700, 1984.
 164. Laragh, J. H.. Atrial natriuretic hormone, the renin‐aldosterone axis and blood pressure–electrolyte homeostasis. N. Engl. J. Med. 313: 1330–1340, 1985.
 165. Lasarides, A., J. J., Brown, D. L. Davies, R. Fraser, J. I. S. Robertson, A. F. Lever. Arterial blood pressure and plasma and body electrolytes in idiopathic hyperaldosteronism: a comparison with primary hyperaldosteronism (Conn's syndrome) and essential hypertension. J. Hypertens. 2: 329–336, 1984.
 166. Laurent, S., P., Lacolley, P. Brunnel, B. Laloux, and M. E. Safar. Flow‐dependent vasodilation of brachial artery in essential hypertension. Am. J. Physiol. 258 (Heart Circ. Physiol. 29): H1004–H1011, 1990.
 167. Leckie, B. J., and N. K. McGhee. Reversible activation–inactivation of renin in human plasma. Nature 288: 702–704, 1980.
 168. Lenz, T., J. E., Sealey, T. Maack, G. D. James, R. L. Henrikson, D. Marion, and J. H. Laragh. Half‐life, haemodynamic renal and hormonal effects on prorenin in cynomolgus monkeys. Am. J. Physiol. 26. (Regulatory Integrative Comp. Physiol. 29): R804–R810, 1990.
 169. Lee, S. M., E., Lightner, M. Witte, S. Oberfield, L. Levine and M.I. New. Dexamethasone‐suppressible hyperaldosteronism in a child with nephrosclerosis. Acta Endocrinol. (Copenh.) 99: 251–255, 1982.
 170. Leroy‐Willig, A., J., Bittoun, J.‐P. Luton, A. Louvel, J. E. Lefevre, A. Bonnin, and J. C. Roucayrol. In vivo MR spectroscopic imaging of the adrenal glands. AJR Am. J. Roentgenol. 153: 771–773, 1989.
 171. Lifton, R. P., and X. Jeunemaitre. Finding genes that cause hypertension. J. Hypertens. 11: 231–236, 1993.
 172. Lifton, R. P., R. G., Dluhy, M. Powers, G. M. Rich, S. Cook, S. Ulick, and J.‐M. Lalouel. A chimaeric 11β‐hydroxylase/aldosterone synthase gene causes glucocorticoid‐remediable aldosteronism and human hypertension. Nature 355: 262–265, 1992.
 173. Lindpaintner, K.. Genetic linkage analysis in hypertension: principles and practice. J. Hypertens. 10: 121–124, 1992.
 174. Longo, D. L., J. A., Esterly, C. E. Grim, and W. F. Keitzer. Pathology of the adrenal gland in refractory low renin hypertension. Arch. Pathol. Lab. Med. 102: 322–377, 1978.
 175. Lumbers, E. R.. Activation of renin in human amniotic fluid by low pH. Enzymologia 40: 329–336, 1971.
 176. Luscher, T. F., B. S., Oemar, C. M. Boulanger, and A. W. A. Hahn. Molecular and cellular biology of endothelin and its receptors—part I. J. Hypertens. 11: 7–11, 1993.
 177. Luscher, T. F., B. S., Oemar, C. M. Boulanger, and A. W. A. Hahn. Molecular and cellular biology of endothelin and its receptors—part II. J. Hypertens. 11: 121–126, 1993.
 178. Luscher, T. F., L., Raij, and P.M. Vanhoutte. Endothelium‐dependent vascular responses in normotensive and hypertensive Dahl rats. Hypertension 9: 157–163, 1987.
 179. Luscher, T. F., B., Seo, and R. Buhler. Potential role of endothelin in hypertension. Hypertension 211: 752–757, 1993.
 180. Makita, N., N., Iwai, T. Inagami, and K. F. Badr. Two distinct pathways in the down‐regulation of type I angiotensin II receptor gene in rat glomerular mesangial cells. Biochem. Biophys. Res. Commun. 185: 142–146, 1992.
 181. Mancia, G., G. Grassi, G. Parati, and A. Daffonchio. Evaluating sympathetic activity in human hypertension. J. Hypertens. 11 (Suppl. 5): S13–S19, 1993.
 182. Manger, W. M., and R. W. Gifford, Phaeochromocytoma: a clinical overview. In: Textbook of Hypertension, edited by J. D. Swales. Oxford: Blackwell, 1994, p. 941–958.
 183. Manunta, P., A. C., Rogowski, B. P. Hamilton, and J. M. Hamlyn. Ouabain‐induced hypertension in the rat: relationships among plasma and tissue ouabain and blood pressure. J. Hypertens. 12: 549–560, 1994.
 184. Masaki, T.. Endothelins: homeostatis and compensatory actions in the circulatory and endocrine systems. Endocr. Rev. 14: 256–268, 1993.
 185. Mattei, M.‐G., C., Hubert, F. Alhenc‐Gelas, N. Roeckel, and P. Corvol. Angiotensin I converting enzyme gene is on chromosome 17. Cytogenet. Cell Genet. 51: 1041, 1989.
 186. May, C. N., and J. A. Bednorik. Effects of infusions of combinations of adrenocorticosteroids on blood pressure, cardiac output and regional blood flow in conscious sheep. J. Hypertens. (in press), 14, 475–482 1996.
 187. McGuffin, W. L., B. M., Sherman, J. Roth, P. Gordon, C. R. Kahn, W. C. Roberts, and P. L. Frommer. Acromegaly and cardiovascular disorders: a prospective study. Ann. Intern. Med. 81: 11–18, 1974.
 188. McKay, A., J. J., Brown, A. F. Lever, J. J. Morton, and J. I. S. Robertson, Unilateral renal disease in hypertension. In: Handbook of Hypertension. Clinical Aspects of Secondary Hypertension, edited by J. I. S. Robertson. Amsterdam: Elsevier, 1983, vol. 2, p. 33–79.
 189. McNicol, A. M., The human adrenal cortex. Aspects of structure, function and pathology. In: The Adrenal Cortex, edited by V. H. T. James. New York: Raven, 1992, p. 1–42.
 190. Michel, M. C., O.‐E., Brodde, and P. A. Insel. Peripheral adrenergic receptors in hypertension. Hypertension 16: 107–120, 1990.
 191. Miyoshi, Y., Y., Nakaya, T. Wakasula, S. Nakaya, K. Fujino, K. Saito, and I. Inoue. Endothelin blocks ATP‐sensitive K;+ channels and depolarises smooth muscle cells of porcine coronary artery. Circ. Res. 70: 612–616, 1992.
 192. Mizuno, K., M., Nakamura, K. Higashimori, and T. Inagami. Local generation and release of angiotensin II in peripheral vascular tissues. Hypertension 11: 223–229, 1988.
 193. Miyazake, H., A., Fukamizu, S. Hirose, T. Hayastu, H. Hori, and Ohkubo, H., Nakanishi S., Murakami K.. Structure of the human renin gene. Proc. Natl. Acad. Sci. U.S.A. 81: 5999–6003, 1984.
 194. Moncada, S., R. M. J., Palmer, and E. A. Higgs. Nitric oxide: physiology, pathophysiology, pharmacology. Pharmacol. Rev. 43: 109–142, 1991.
 195. Montorsi, P., G., Tonolo, J. Polonia, D. Hepburn, and A. M. Richards. Correlates of plasma atrial natriuretic factor in health and hypertension. J. Hypertens. 10: 570–576, 1987.
 196. Moore, T. J., and G. H. Williams, Acromegaly and hypertension. In: Handbook of Hypertension. Secondary Hypertension, edited by J. I. S. Robertson. Amsterdam: Elsevier, 1983, p. 222–237.
 197. Mornet, E., J., Dupont, A. Vitek, and P. White. Characterisation of two genes encoding human steroid 11β‐hydroxylase. J. Biol. Chem. 264: 20961–20967, 1989.
 198. Morris, A. D., J. R., Petrie, and J. M. C. Connell. Insulin and hypertension. J. Hypertens. 12: 633–642, 1994.
 199. Muller, J.. Aldosterone: the minority hormone of the adrenal cortex. Steroids 60: 2–9, 1995.
 200. Mulrow, P. J., and R. Franco‐Saez. The adrenal renin‐angiotensin system: a local hormonal regulator of aldosterone production. J. Hypertens. 14: 173–176, 1996.
 201. Mune, T., F. M., Rogerson, H. Nikkila, A. K. Agarwal, and P. C. White. Human hypertension caused by a mutation in the kidney isozyme of 11β‐hydroxysteroid dehydrogenase. Nat. Genet. 10: 394–399, 1995.
 202. Naftalin, A. J.. The role of angiotensin II in vascular smooth muscle cell growth. J. Cardiovasc. Pharmacol. 20: S37–S40, 1992.
 203. Nakao, K., Y., Ogawa, S. Suga, and H. Imura. Molecular biology and biochemistry of the natriuretic peptide system. J. Hypertens. 10: 907–912, 1992.
 204. Natali, A., D., Sautro, C. Palambo, M. Cerri, S. Ghione, and E. Ferranini. Impaired insulin action on skeletal muscle metabolism in essential hypertension. Hypertension 17: 176–178, 1991.
 205. Ng, L. L., and D. J. Evans. Leucocyte sodium transport in acromegaly. Clin. Endocrinol. (Oxf.) 26: 471–480, 1987.
 206. Nicholls, M. G.. The natriuretic peptides in heart failure. J. Intern. Med. 235: 515–526, 1994.
 207. Nicholls, M. G., and A. M. Richards. Human studies with atrial natriuretic factor. Endocrinol. Metab. Clin. North Am. 16L: 199–223, 16L: 1987.
 208. Nicholls, M. G., A. M. Richards, K. N. Lai, Drug‐induced hypertension. In: Handbook of Hypertension. Secondary Hypertension, edited by J. I. S. Robertson. Amsterdam: Elsevier, 1992, p. 195–235.
 209. O'Hare, J. A., J. B., Ferris, D. Brady, B. Twomey, D. J. O'Sullivan. Exchangeable sodium and renin in hypertensive diabetic patients with and without retinopathy. Hypertension 7 (Suppl. II): II–43–II–48, 1985.
 210. Ohno, Y., H., Suzuki, H. Yamakawa, M. Nakamura, K. Otsuka, and T. Saruta. Impaired insulin sensitivity in young, lean normotensive offspring of essential hypertensives: possible role of disturbed calcium metabolism. J. Hypertens. 11: 421–426, 1993.
 211. Owens, G. K., and S. M. Schwarz. Alterations in vascular smooth muscle mass in the spontaneously hypertensive rat. Role of cellular hypertrophy, hyperploidy and hyperplasia. Circ. Res. 51: 280–289, 1982.
 212. Panarelli, M., and R. Fraser. The glucocorticoid receptor and hypertension. Endocr. Res. 20: 101–116, 1994.
 213. Panarelli, M., C. D., Holloway, A. P. B. Barr, R. Fraser, and C. J. Kenyon. Differences in temperature‐sensitive receptor binding of glucocorticoids in spontaneously hypertensive and normotensive Wistar Kyoto rats. Steroids 60: 73–75, 1995.
 214. Paul, M., J., Wagner, M. Bader, and D. Ganten, Transgenic animal models for hypertension. In: Textbook of Hypertension, edited by J.D. Swales. London: Blackwell, 1994, p. 469–476.
 215. Paquet, J. L. M. Bandonim‐Legros, G. Brunella, and P. Meyer. Angiotensin II‐induced proliferation of aortic myocytes in spontaneously hypertensive rats. J. Hypertens. 8: 565–572, 1990.
 216. Pascoe, L., and K. M. Curnow. Genetic recombination as a cause of inherited disorders of aldosterone and Cortisol biosynthesis and as a contributor to genetic variation in blood pressure. Steroids 60: 22–27, 1995.
 217. Pascoe, L., K. M., Curnow, L. Slutsker, J. M. C. Connell, P. Speiser, M. I. New, and P. White. Glucocorticoid‐suppressible hyperaldosteronism results from hybrid genes created by unequal crossovers between CYP11B1 and CYP11B2. Proc. Natl. Acad. Sci. U.S.A. 89: 8327–8331, 1992.
 218. Peach, M. J., and D. E. Dostal. The angiotensin II receptor and the actions of angiotensin II. J. Cardiovasc. Pharmacol. 16: (Suppl. 4): 525–530, 1990.
 219. Pratt, W. B.. Interaction of hsp90 with steroid receptors: organising some diverse observations and presenting the newest points. Mol. Cell. Endocrinol. 74: c69–c76, 1990.
 220. Pratt, W. B.. The role of heat shock protein in regulating the functions, folding and trafficking of the glucocorticoid receptor. J. Biol. Chem. 268: 21455–21458, 1993.
 221. Quilley, J., and J. C. McGiff, Eicosanoids. In: Textbook of Hypertension, edited by J. D. Swales. London: Blackwell, 1994, p. 314–327.
 222. Quinn, S. J., and G. H. Williams, Regulation of aldosterone secretion. In: The Adrenal Cortex, edited by V. H. T. James. New York: Raven, 1992, p. 159–189.
 223. Radomski, M. W., M. J., Palmer, and S. Moncada. Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proc. Natl. Acad. Sci. U.S.A. 87: 10043–10067, 1990.
 224. Raymond, J. R., M., Huatovich, R. J. Lefkovitz, and M. G. Caron. Adrenergic receptors. Models for regulation of signal transduction processes. Hypertension 15: 119–151, 1990.
 225. Re, R., J. T., Fallon, V. Dzau, S. C. Quay, and E. Haber. Renin synthesis by canine aortic smooth muscle cells in culture. Life Sci. 30: 99–106, 1982.
 226. Reaven, G. M.. Role of insulin resistance on human disease Diabetes 37: 1596–1607, 1988.
 227. Reaven, G. M., and H. Chang. Relationships between blood pressure, plasma insulin and triglyceride concentration and insulin action in SHR and WKY rats. Am. J. Hypertens. 4: 34–38, 1991.
 228. Reznek, R. H., and P. Armstrong. Imaging in endocrinolog the adrenal gland. Clin. Endocrinol. (Oxf.) 40: 561–576, 1999.
 229. Richards, A. M., Atrial natriuretic peptides in hypertension. Frontiers in Pharmacology and Therapeutics, edited by Struthers. Oxford: Blackwell, 1990, p. 141–162.
 230. Richards, A. M., I. G., Crozier, S. J. Holmes, E. A. Espir T. G. Yandle, and C. Frampton. Brain natriuretic peptide; triuretic and endocrine effects in essential hypertension. J. Hypertens. 11: 163–170, 1993.
 231. Richards, A. M., I. G. Crozier T. G. Yandle, E. A. Espiner, H. Ikram, and M. G. Nicholls. Brain natriuretic factor: regional plasma concentrations and interrelations with haemodynamic status in cardiac disease. Br. Heart J. 69: 414–417, 1993.
 232. Richards, A. M., M. G., Nicholls, L. Lewis, and J. G. Lainchburg. Adrenomedullin. Clin. Sci. (Colch.) 91: 3–16, 1996.
 233. Richards, A. M., G., Wittert, E. A. Espiner, T. G. Yandle, H. Ikram, and C. Frampton. Endopeptidase 24.11 inhibition alters metabolic clearance and bioactivity of atrial natriuretic peptide in man. J. Clin. Endocrinol. Metab. 72: 1317–1322, 1991.
 234. Richards, A. M., G., Wittert, E. A. Espiner, T. G. Yandle, H. Ikram, and C. Frampton. Effect of inhibition of endopeptidase 24.11 on responses to angiotensin II in human volunteers. Circ. Res. 71: 1501–1507, 1992.
 235. Richards, A. M., G. A., Wittert, I. G. Crozier, E. A. Espiner, T. G. Yandle, H. Ikram, and C. Frampton. Chronic inhibition of endopeptidase 24.11 in essential hypertensives: evidence for enhanced activity of atrial natriuretic factor and angiotensin II. J. Hypertens. 11: 407–416, 1993.
 236. Ritchie, C. M., B., Sheridan, R. Fraser, D. R. Hadden, A. L. Kennedy, J. Ridell, and A. B. Atkinson. Studies on the pathogenesis of hypertension in Cushing's disease and acromegaly. Q. J. Med. 76: 855–867, 1990.
 237. Robertson, J. I. S., Unilateral renal disease in hypertension. In: Handbook of Hypertension. Clinical Hypertension, edited by J. I. S., Robertson. Amsterdam: Elsevier, 1992, vol. 15, p. 266–325.
 238. Robertson, J. I. S., Endothelin‐secreting tumours. In: Handbook of Hypertension. Clinical Hypertension, edited by J. I. S. Robertson. Amsterdam: Elsevier, 1994, vol. 15, p. 619–620.
 239. Rushoako, H.. Atrial natriuretic peptide: synthesis, release, metabolism. Pharmacol. Rev. 44: 481–602, 1992.
 240. Russo, D., R., Fraser, and C. J. Kenyon. Increased sensitivity to noradrenaline in glucocorticoid‐treated rats: the effects of indomethacin and desipramine. J. Hypertens. 8: 827–833, 1990.
 241. Rusvai, E., and A. N. Fejes‐Toth. A new isoform of 11β‐hydroxysteroid dehydrogenase in aldosterone target cells. J. Biol. Ghem. 368: 10717–10720, 1993.
 242. Saad, M. F., S., Lillioja, B. L. Nyomba, C. Castillo, R. Ferraro, and M. de Gregario. Racial differences in the relation between blood pressure and insulin resistance. N. Engl. J. Med. 324: 733–739, 1991.
 243. Safar, M. E.. Abnormal vascular relaxation in essential hypertension. N. Engl. J. Med. 323: 1772–1773, 1990.
 244. Sagnella, G. A., N. D., Markanda, M. G. Buckley, M. A. Miller, D. K. J. Singer, F. P. Cappucio. Atrial natriuretic peptides in essential hypertension: basal plasma levels and relationship to sodium balance. Can. J. Physiol. Pharmacol. 69: 1592–1600, 1991.
 245. Sagnella, G. A., N. D., Markanda, A. C. Shore, and G. A. MacGregor. Raised circulating levels of atrial natriuretic peptides in essential hypertension. Lancet 1: 179–181, 1986.
 246. Sagnella, G. A., and G. A. McGregor, Atrial natriuretic peptides. In: Handbook of Hypertension, edited by J. D. Swales. London: Blackwell, 1994, p. 273–288.
 247. Saito, Y., K., Nakao, M. Mukoyama, and H. Imwa. Increased plasma endothelin levels in patients with essential hypertension. N. Engl. J. Med. 322: 205, 1990.
 248. Salomaa, V. V. T. E. Strandberg, H. Vanhanen, V. Naukkaranen, S. Sama, and T. A. Mieltinen. Glucose intolerance and blood pressure: long term follow up in middle aged men. BMJ 302: 493–496, 1991.
 249. Samani, N. J., Extrarenal renin‐angiotensin systems. In: Textbook of Hypertension, edited by J. D. Swales. London: Blackwell, 1994, p. 253–272.
 250. Sassano, H.. New approaches in human adrenocortical pathology: assessment of adrenocortical function in surgical specimen of human adrenal glands. Endocr. Pathol. 3: 4–13, 1992.
 251. Schelling, P., H., Fischer, and D. Ganten. Angiotensin and cell growth: a link to cardiovascular hypertrophy? J. Hypertens. 9: 3–15, 1991.
 252. Schneider, S. H., and D. S. Bredt. Biological roles of nitric oxide. Sci. Am. 266: 28–35, 1992.
 253. Schonig, A., B., Luth, R. Detz, and F. Gross. Changes in vascular smooth muscle sensitivity to vasconstrictor agents induced by corticosteroids, adrenalectomy and differing salt, intake in rats. Clin. Sci. Mol. Med. 5: 61S–63S, 1976.
 254. Scoggins, B. A., D. A. Denton J. A. Whitworth, and J. P. Coghlan. ACTH‐dependent hypertension. Clin. Exp. Hypertens. A6: 599–649, 1984.
 255. Sealey, J. E.. Evidence for the cardiovascular effects of proprenin. J. Hum. Hypertens. 9: 381–384, 1995.
 256. Sealey, J. E., and S. Rubatta. Prorenin and renin as separate mediators of tissue and circulating systems. Am. J. Hypertens. 2: 358–366, 1989.
 257. Sessa, W. C., L., Lin, and A. Nasjletti. Reciprocal effects of dexamethasone on vasodilatory response to arachidonic acid and prostanoids in isolated perfused rabbit kidney. Hypertension 15: 193–196, 1990.
 258. Skinner, S. L., E. R., Lumbers, and E. M. Symonds. Renin concentration in human foetal and maternal tissues. Am. J. Obstet. Gynecol. 101: 529–533, 1968.
 259. Skinner, S. L., J. W., McCubbin, and I. H. Page. Control of renin secretion. Circ. Res. 15: 64–76, 1964.
 260. Smith, W. I.. Prostanoid biosynthesis and mechanism of action. Am. J. Physiol. 263 (Renal Fluid Electrolyte Physiol. 34): F633–F642, 1992.
 261. Snow, M. H., D. A., Piercy, V. Robsin, and R. Wilkinson. An investigation into the pathogenesis of hypertension in acromegaly. Clin. Sci. (Colch.) 53: 87–91, 1977.
 262. Soro, A., M. C., Ingram, G. Tonolo, N. Glorioso, and R. Fraser. Evidence of coexisting changes in 11β‐hydroxysteroid dehydrogenase and 5β‐reductase activity in subjects with untreated essential hypertension. Hypertension 25: 67–70, 1995.
 263. Stewart, P. M., J. E. T., Corrie, C. H. L. Shackleton, and C. R. W. Edwards. The syndrome of apparent mineralocorticoid excess: a defect in the Cortisol: cortisone shuttle. J. Clin. Invest. 82: 340–349, 1988.
 264. Stewart, P. M. Z. S. Krozowski, and A. Gupta. Hypertension in the syndrome of apparent mineralocorticoid excess due to a mutation in the 11β‐hydroxysteroid dehydrogenase type 2 gene. Lancet 347: 88–91, 1996.
 265. Stewart, P. M., and J. I. Mason. Cortisol to cortisone: glucocorticoid to mineralocorticoid. Steroids 60: 143–146, 1995.
 266. Stewart, P. M., B. A., Murray, and J. I. Mason. Human kidney 11β‐hydroxysteroid dehydrogenase is a high affinity NAD‐dependent enzyme and differs from cloned type I isoform. J. Clin. Endocrinol. Metab. 79: 480–484, 1994.
 267. Stewart, P. M., R., Valentino, A. M. Walker, D. Burt, C. H. Shackleton, and C. R. W. Edwards. Mineralocorticoid activity of liquorice: 11β‐hydroxysteroid dehydrogenase deficiency comes of age. Lancet 2: 821–824, 1987.
 268. Stewart, P. M., B. R., Walker, G. Holder, D. O'Halloram, and C. H. L. Shackleton. 11β‐Hydroxysteroid dehydrogenase activity in Cushing's syndrome: explaining the mineralocorticoid excess state of the ectopic adrenocorticotrophic syndrome. J. Clin. Endocrinol. Metab. 80: 3617–3620, 1995.
 269. Strasser, R. H., R., Ihl‐Vahl, and R. Marquetant. Molecular biology of adrenergic receptors. J. Hypertens. 10: 501–506, 1992.
 270. Sugawara, A., K., Nakao, T. Kuno, N. Morii, T. Yamade, H. Itoh, S. Shiono, Y. Saito, M. Mukoyama, H. Arai, and H. Imura. Atrial natriuretic factor in essential hypertension and adrenal disorders. Hypertension 11 (Suppl. I) I‐122–I‐126, 1988.
 271. Sutherland, D. J. A., J. L., Ruse, and J. C. Laidlaw. Hypertension, increased aldosterone secretion and low plasma renin activity reversed by dexamethasone. Can. Med. Assoc. J. 95: 1109–1119, 1966.
 272. Suzuki, L. H., J., Kajikari, A. Suzuki, and T. Itoh. Effects of endothelin I on endothelial cells in the porcine coronary artery. Circ. Res. 69: 1361–1368, 1991.
 273. Tagaki, M., H., Matsuoko, K. Atarashi, and S. Yagi. Endothelin: a new inhibitor of renin release. Biochem. Biophys. Res. Commun. 157: 1164–1168, 1988.
 274. Takeda, Y., I., Miyamori, T. Yoneda, K. Iki, H. Hatakeyama, I. A. Blair, F.‐Y. Hsieh and R. Takeda. Production of aldosterone in isolated rat blood vessels. Hypertension 25: 170–173, 1995.
 275. Tannin, G. M., A. K., Agarwal, C. Monder, M. I. New, and P. C. White. The human gene for 11β‐hydroxysteroid dehydrogenase. Structure, tissue distribution and chromosomal localisation. J. Biol. Chem. 166: 16653–16658, 1991.
 276. Taylor, A. A., and F. C. Bartter, Hypertension in licorice intoxication, acromegaly and Cushing's syndrome. In: Hypertension, edited by J. Genest, E. Roiw, and O. Kuchel. New York: McGraw‐Hill, 1977, p. 755–767.
 277. Thierauch, K.‐H., H. Dinter, and G. Stock. Prostaglandins and their receptors I: pharmacologic receptor description and drug use. J. Hypertens. 11: 11315–1318, 1993.
 278. Thurston, H., Goldblatt, coarctation and Page experimental models of renovascular hypertension. In: Handbook of Hypertension, edited by J. D. Swales. London: Blackwell, 1994, p. 477–493.
 279. Timmermans, P. B. M. W. M., P. C., Wong, A. T. Chiu, W. F. Herblin, P. Benfield, D. J. Carini, R. J. Lee, R. R. Wexler, J. A. M. Saye, and R. D. Smith. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol. Rev. 45: 205–251, 1993.
 280. Tonolo, G., R., Fraser, J. M. C. Connell, and C. J. Kenyon. Chronic low‐dose infusions of dexamethasone in rats: effects on blood pressure, body weight and atrial natriuretic peptide. J. Hypertens. 6: 25–31, 1988.
 281. Traylor, T. G. and V. S., Sharma. Why NO? Biochemistry 31: 2847–2849, 1992.
 282. Tsutamoto, T., Y., Maeda, A. Wada, Y. Nakamura, and M. Kinoshita. Plasma brain natriuretic peptide concentration as a prognostic predictor in patients with chronic congestive heart failure. Circulation 84: 1–26, 1993.
 283. Ulick, S., and M. D. Chu. Hypersecretion of a new corticosteroid, 18‐hydroxycortisol, in two types of adrenocortical hypertension. Clin. Exp. Hypertens. A4: 1771–1777, 1982.
 284. Ulick, S., L. S., Levine, P. Gunczler, G. Zanconato, L. C. Ramirez, W. Rauh, A. Rosier, H. H. Bradlow, and M. I. New. A syndrome of apparent mineralocorticoid excess with defects in the peripheral metabolism of Cortisol. J. Clin. Endocrinol. Metab. 49: 757–764, 1979.
 285. Ulick, S., L. C., Ramirez, and M. I. New. An abnormality in steroid metabolism in a hypertensive syndrome. J. Clin. Endocrinol. Metab. 44: 799–802, 1977.
 286. Vallance, P., J., Collier, and S. Moncada. Effects of endothelium‐derived nitric oxide on peripheral arteriolar tone in man. Lancet 2: 997–999, 1989.
 287. Van Rentergham, C., P. Vigne, J. Borhanin, A. Schmid‐Alliana, C. Frelin, and M. Ladzdunski. Molecular mechanisms of action of the vasoconstrictor peptide, endothelin. Biochem. Biophys. Res. Commun. 157: 977–985, 1988.
 288. Van Zwieten, P. A., M. Safar, S. Laurent, M. Pfaffendorf, M. G. C. Hendriks, and Bruning. New insights into the role of endothelial dysfunction in hypertension. J. Hypertens. 13: 713–716, 1995.
 289. Vecsei, P., and K. Frank, D. Haack, V. Heinze, A.‐D. Ho, J. W. Honour, S. Lewicka, M. Schoosch, and R. Ziegler. Primary glucocorticoid receptor defect with likely familial involvement. Cancer Res. 49: 2220S–2221S, 1989.
 290. Velchik, M. G., H. Y., Kressel, A. W. Noel, and A. Alavi. Primary aldosteronism. CT, MRI, scintigraphic correlation. Invest. Radiol. 20: 237–241, 1995.
 291. Victor, R. G., and A. L. Mark, The sympathetic nervous system in human hypertension. In: Hypertension. Pathophysiology, Diagnosis and Management, edited by . H. Laragh, and B. M. Brenner. New York: Raven, 1995, p. 863–878.
 292. Vidal, M. J., J. C., Romero, and P. M. Vanhoutte. Endothelium‐derived relaxing factor inhibits renin release. Eur. J. Pharmacol. 149: 401–402, 1988.
 293. Vinson, G. P., B., Whitehouse, and J. Hinson, The Adrenal Cortex. Englewood Cliffs, NJ: Prentice Hall, 1992.
 294. Waldmann, S. A., and F. Murad. Atrial natriuretic peptides: receptors and second messengers. Bioessays 10: 16–19, 1989.
 295. Walker, B. R., J. C., Campbell, R. Fraser, P. M. Stewart, and C. R. W. Edwards. Mineralocorticoid excess and inhibition of 11β‐hydroxysteroid dehydrogenase in patients with ectopic ACTH syndrome. Clin. Endocrinol. (Oxf.) 37: 483–492, 1992.
 296. Walker, B. R., P. M., Stewart, P. L. Padfield and C. R. W. Edwards. 11β‐Hydroxysteroid dehydrogenase in essential hypertension. J. Endocrinol. 129: 282s, 1991.
 297. Wallnofer, A., S., Weir, U. Ruegg, and C. Calvin. Molecular mechanisms of action of the vasoconstrictor peptide, endothelin. J. Cardiovasc. Pharmacol. 15 (Suppl. 5): 23–31, 1989.
 298. Wehling, M., J., Kasmayr, M. Christ, W. Sippell, K. Theisen, and O. A. Muller. The early mineralocorticoid effector mechanism, the sodium‐proton exchanger is sensitized in lymphocytes from patients with Cushing's syndrome. Clin. Endocrinol. (Oxf.) 37: 260–265, 1992.
 299. Wenting, G. J., A. J. Man in't Veld, R. P. Verhoeven, F. H. M. Derkx, and M. A. D. H. Schalekamp. Volume–pressure relationships during development of mineralocorticoid hypertension in man. Circ. Res. 40 (Suppl. I) I‐163–I‐170, 1977.
 300. Werner, S., M., Thoren, J. A. Gustafsson, and M. Bronnegard. Glucocorticoid receptor abnormalities in fibroblasts from patients with idiopathic resistance to dexamethasone diagnosed when evaluated for adrenocortical disorders. J. Clin. Endocrinol. Metab. 75: 1005–1009, 1992.
 301. White, P., K., Curnow, and L. Pascoe. Disorders of steroid 11β‐hydroxylase isozyme. Endocr. Rev. 15: 421–438, 1994.
 302. Whitworth, J. A.. Mechanisms of glucocorticoid‐induced hypertension. Kidney Int. 31: 1213–1234, 1987.
 303. Whitworth, J. A., M. A., Brown, J. J. Kelly, and P. M. Williamson. Mechanisms of cortisol‐induced hypertension in humans. Steroids 60: 76–80, 1995.
 304. Whitworth, J. A., J. M. C., Connell, D. Gordon, and B. A. Scoggins. Effects of indomethacine on steroid‐induced changes in pressor responsiveness in man. Clin. Exp. Pharmacol. Physiol. 15: 305–310, 1988.
 305. Whitworth, J. A., J. M. C., Connell, A. F. Lever, and R. Fraser. Pressor responsiveness in steroid‐induced hypertension. Clin. Exp. Pharmacol. Physiol. 13: 353–358, 1986.
 306. Wilhelmsen, L. Synergistic effects of risk factors, Clin. Exp. Hypertens. A12: 845–863, 1990.
 307. Williams, E. D., K., Boddy, J. J. Brown, A. M. M. Cumming, D. L. Davies, I. R. Harvey, J. K. Haywood, A. F. Lever, and J. I. S. Robertson. Body elemental composition with particular reference to total and exchangeable sodium and potassium and total chlorine in untreated and treated primary hyperaldosteronism. J. Hypertens. 2: 171–176, 1984.
 308. Williams, R. R., S. C., Hunt, S. J. Hasstedt, P. N. Hopkins, L. L. Wu, T. D. Berry, B. M. Stults, G. K. Barlow, and H. Kuida. Genetics of hypertension: what we know and what we don't know. Clin. Exp. Hypertens. A12: 865–876, 1990.
 309. Wilson, R. C., Z. S., Krozowski, K. Li, V. R. Obeyesekere, M. Rassaghy‐Azar, M. D. Harbison, J. Q. Wei, C. H. L. Shackleton, J. W. Funder, and M. I. New. A mutation in the 11HSDB2 gene in a family with apparent mineralocorticoid excess. J. Clin. Endocrinol. Metab. 80: 2263–2266, 1995.
 310. Wu, K., Y., Chen, J. Chu, K. Hung, T. Hsieh, and B. Hsieh. Zona fasciculata‐like cells determine the response of plasma aldosterone to metoclopramide and aldosterone synthase messenger ribonucleic acid level in aldosterone‐producing adenoma. J. Clin. Endocrinol. Metab. 80: 783–789, 1995.
 311. Yamaguchi, T., Z., Naito, G. D. Stoner, R. Franco‐Saez, and P. J. Mulrow. Role of the adrenal renin–angiotensin system and potassium‐stimulated aldosterone production by rat adrenal glomerulsoa cells in monolayer culture. Hypertension 16: 635–641, 1990.
 312. Yanaji, T., M., Ishibashi, H. Sekihari, F. Takaku, H. Nakaoka, and J. Fuji. Plasma levels of atrial natriuretic factor in primary aldosteronism and essential hypertension. J. Clin. Endocrinol. Metab. 63: 815–818, 1986.
 313. Yanase, T., M., Waterman, M. Zachmann, J. Winter, E. Simpson, M. Kagimoto. Molecular basis of apparent isolated 17,20 lyase deficiency: compound heterozygous mutations in the C‐terminal region actually cause combined 17α‐hydroxylase/17,20 lyase deficiency. Biochim. Biophys. Acta 1139: 275–279, 1992.
 314. Yasunari, K., M. Kohono, Murahawak, K. Yokohawa, and T. Takeda. Effect of glucocorticoid on prostagladin E1‐mediated cyclic AMP formation by vascular smooth muscle cells. J. Hypertens. 6: 1023–1028, 1988.
 315. Zhou, M. Y., E. P. Gomez Sanchez, M. F. Foeking, and C. E. Gomez. Cloning and expression of the rat brain and adrenal cytochrome P450c11B3 (CYP11B3) enzyme cDNA: preferential 18‐hydroxylation over 11β‐hydroxylatin of DOC. Mol. Cell. Endocrinol. 114: 137–145, 1995.

Contact Editor

Submit a note to the editor about this article by filling in the form below.

* Required Field

How to Cite

Robert Fraser. Endocrine Hypertension. Compr Physiol 2011, Supplement 22: Handbook of Physiology, The Endocrine System, Endocrine Regulation of Water and Electrolyte Balance: 228-249. First published in print 2000. doi: 10.1002/cphy.cp070306